Tirzepatide

Fat LossFDA-Approved

Overview

Tirzepatide (brand names Mounjaro® for T2D, Zepbound® for weight management) is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It is FDA-approved for type 2 diabetes management and chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Evidence Strength

🟢

Human Clinical Evidence

Supported by peer-reviewed human clinical trials

🟢Human Clinical Evidence

🟡Limited Human Evidence

🟠Mostly Animal Research

🔴Preclinical / Laboratory

This information is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making any health decisions.